Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
mTORC1 hyperactivation arrests bone growth in lysosomal storage disorders by suppressing autophagy
Rosa Bartolomeo, Laura Cinque, Chiara De Leonibus, Alison Forrester, Anna Chiara Salzano, Jlenia Monfregola, Emanuela De Gennaro, Edoardo Nusco, Isabella Azario, Carmela Lanzara, Marta Serafini, Beth Levine, Andrea Ballabio, Carmine Settembre
Rosa Bartolomeo, Laura Cinque, Chiara De Leonibus, Alison Forrester, Anna Chiara Salzano, Jlenia Monfregola, Emanuela De Gennaro, Edoardo Nusco, Isabella Azario, Carmela Lanzara, Marta Serafini, Beth Levine, Andrea Ballabio, Carmine Settembre
View: Text | PDF
Concise Communication Bone biology

mTORC1 hyperactivation arrests bone growth in lysosomal storage disorders by suppressing autophagy

  • Text
  • PDF
Abstract

The mammalian target of rapamycin complex 1 (mTORC1) kinase promotes cell growth by activating biosynthetic pathways and suppressing catabolic pathways, particularly that of macroautophagy. A prerequisite for mTORC1 activation is its translocation to the lysosomal surface. Deregulation of mTORC1 has been associated with the pathogenesis of several diseases, but its role in skeletal disorders is largely unknown. Here, we show that enhanced mTORC1 signaling arrests bone growth in lysosomal storage disorders (LSDs). We found that lysosomal dysfunction induces a constitutive lysosomal association and consequent activation of mTORC1 in chondrocytes, the cells devoted to bone elongation. mTORC1 hyperphosphorylates the protein UV radiation resistance–associated gene (UVRAG), reducing the activity of the associated Beclin 1–Vps34 complex and thereby inhibiting phosphoinositide production. Limiting phosphoinositide production leads to a blockage of the autophagy flux in LSD chondrocytes. As a consequence, LSD chondrocytes fail to properly secrete collagens, the main components of the cartilage extracellular matrix. In mouse models of LSD, normalization of mTORC1 signaling or stimulation of the Beclin 1–Vps34–UVRAG complex rescued the autophagy flux, restored collagen levels in cartilage, and ameliorated the bone phenotype. Taken together, these data unveil a role for mTORC1 and autophagy in the pathogenesis of skeletal disorders and suggest potential therapeutic approaches for the treatment of LSDs.

Authors

Rosa Bartolomeo, Laura Cinque, Chiara De Leonibus, Alison Forrester, Anna Chiara Salzano, Jlenia Monfregola, Emanuela De Gennaro, Edoardo Nusco, Isabella Azario, Carmela Lanzara, Marta Serafini, Beth Levine, Andrea Ballabio, Carmine Settembre

×

Figure 4

Normalization of mTORC1 signaling restores collagen trafficking and rescues bone phenotype in MPS VII mice.

Options: View larger image (or click on image) Download as PowerPoint
Normalization of mTORC1 signaling restores collagen trafficking and resc...
(A) Representative images of femoral growth plate sections isolated from Gusb+/+, Gusb–/–, and Gusb–/– Rpt+/– mice at P15. P-S6 immunostaining (arrows, brown, top row), intracellular PC2 (green, second row), COL X (third row), and COL II (brown, bottom row). Nuclei were counterstained with hematoxylin (pink, top row and bottom row) or DAPI (blue, second row). Scale bars: 100 μm. Insets show magnification ×3. (B) Bar graphs show the length of the HZ (COL X+ area). n = 5 mice per genotype. (C) Quantification of collagen isolated from femoral and tibia cartilages from mice of the indicated genotypes and expressed as the percentage of Gusb+/+ mice. n ≥ 5 mice per genotype. (D) Representative images of SQSTM1/p62 and Lamp-1 immunofluorescence in femoral growth plates isolated from Gusb–/– and Gusb–/– Rpt+/– mice at P15. n = 3 mice per group. Scale bars: 10 μm; zoom, ×5. (E) Quantification of P62–Lamp-1 colocalization. (F) Representative images of Alcian blue and alizarin red staining of femurs and tibiae from P15 Gusb+/+, Gusb–/–, and Gusb–/– Rpt+/– mice. (G) Femur and tibia lengths for mice of the indicated genotypes. n = 6 mice per genotype. (H) Representative images of Alcian blue and alizarin red staining of femurs and tibiae from P30 Gusb+/+, Gusb–/–, and Gusb–/– Rpt+/– mice. (I) Femur and tibia lengths for mice of the indicated genotypes. n = 6 mice per genotype. Data represent the mean values derived from the indicated number of mice. Error bars indicate the SEM. *P ≤ 0.05, **P ≤ 0.005, and ***P ≤ 0.0005, by ANOVA followed by Tukey’s post-hoc test (B, C, G, and I) and unpaired Student’s t test (E).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts